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HEPATITIS C
A n estimated 3% of the world's population -more than 170 million people -are infected by the hepatitis C virus (HCV). Most infections become chronic: a condition that is incurable in many patients, leading to cirrhosis, end-stage liver disease and hepatocellular carcinoma. Current medical treatment options are limited, and 10,000 to 20,000 deaths a year in the United States are from hepatitis C. Indeed, chronic HCV infection is the most common cause of liver transplantation.
Despite the discovery of the virus by molecular biological methods more than 15 years ago, and the sequencing of its entire genome, our knowledge of the virus and the nature of the protective immune responses is limited. Researchers have been hampered by the lack of a robust cell-culture system yielding infectious virus until very recently, and the absence of a non-primate animal model. Nevertheless, great strides have been made over the past few years, and much has been learned about the viral life cycle, immune response factors that confer protection, and the mechanisms by which the virus is able to evade the host immune response. New drugs are on the horizon and a protective vaccine may be within reach. This Insight brings together leading experts in hepatitis C to provide a snapshot of the field and discuss imminent developments.
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